GlassScriptPhysician profile
Marshall A Silverman
NPI 1669435749
$4,969.22
in general payments reported to CMS, 2019-2025
55 companies · $726 in 2025
The $726 reported for 2025 was more than what 80% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $518 · 2020: $519 · 2021: $801 · 2022: $841 · 2023: $787 · 2024: $778 · 2025: $726.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,291.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,290.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $748.63 | 2019-2025 | Ubrelvy, Vraylar |
| Novo Nordisk INC | $715.77 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $369.58 | 2019-2025 | Evenity, Otezla, Repatha |
| Pfizer INC. | $330.23 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $238.11 | 2019-2025 | Breztri, Airsupra |
| Lilly USA, LLC | $195.02 | 2019-2024 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $189.36 | 2019-2023 | Arexvy, Shingrix |
| Novartis Pharmaceuticals Corporation | $144.82 | 2022-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $143.29 | 2020-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $120.69 | 2019-2025 | Xifaxan, Trulance |
| Abbott Laboratories | $110.08 | 2022-2025 | Freestyle Libre 3, Eterna |
| Kowa Pharmaceuticals America, INC. | $96.93 | 2019-2022 | |
| Daiichi Sankyo INC. | $96.46 | 2021-2023 | Injectafer |
| Exact Sciences Corporation | $90.29 | 2024-2025 | Cologuard Collection Kit |
| Biohaven Pharmaceutical Holding Company LTD. | $86.10 | 2022 |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marshall Silverman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.